← FDA DRUG APPROVALS

FDA ANDA · ANDA203814

SILDENAFIL

Sponsor: MACLEODS PHARMS LTD

APPLICATION
ANDA203814
TYPE
ANDA
ORIGINAL APPROVAL
2013-12-17
LATEST ACTION
2025-06-30
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SILDENAFIL CITRATEPrescription
SILDENAFIL CITRATE EQ 20MG BASE · TABLET · ORAL

Approval history

2025-06-30Labeling · Supplement 29 · standardAP
2025-06-30Labeling · Supplement 27 · standardAP
2025-06-30Labeling · Supplement 23 · standardAP
2019-04-23Labeling · Supplement 12 · standardAP
2019-04-23Labeling · Supplement 9 · standardAP
2019-04-23Labeling · Supplement 5 · standardAP
2015-10-26Labeling · Supplement 2 · standardAP
2015-04-02Labeling · Supplement 1 · standardAP
2013-12-17UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →